IPR decision (Mar. 09, 2018):
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
Patent No.
|
Final Written
Decision
|
|
IPR2016-01771
|
09/09/2016
|
03/16/2017
|
Hospira Inc.
|
US 7,622,115
|
Claims 1–5 are unpatentable
|
US 7,622,115 (Genentech Inc; Exp:
May 28, 2024)
1. A method for treating cancer in a patient comprising
administering an effective amount of bevacizumab and assessing the patient for
gastrointestinal perforation during treatment with bevacizumab.
No comments:
Post a Comment